Sarepta Therapeutics (NASDAQ:SRPT) Given “Sell” Rating at HC Wainwright

HC Wainwright reaffirmed their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $75.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q1 2025 earnings at $2.45 EPS and Q4 2025 earnings at $2.85 EPS.

SRPT has been the subject of a number of other reports. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Evercore ISI lowered their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Finally, Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Trading Up 0.4 %

Shares of NASDAQ:SRPT opened at $119.33 on Wednesday. The company’s 50-day moving average price is $121.75 and its two-hundred day moving average price is $130.06. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $11.40 billion, a PE ratio of 95.46 and a beta of 0.77.

Insider Activity

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. CIBC Asset Management Inc boosted its stake in shares of Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 86 shares during the last quarter. EP Wealth Advisors LLC lifted its holdings in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 103 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Sarepta Therapeutics by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 155 shares during the period. Finally, Huntington National Bank grew its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.